Skip to contentT
TScan Therapeutics, Inc.
T
TCRXTScan Therapeutics, Inc. Q2 2024 · 10-Q
Revenue$536.00K$536.00K−83.0% vs Q2 2023 Net Income-$31.66M-$31.66MN/M vs Q2 2023 EPS Diluted-$0.28-$0.28N/M vs Q2 2023 Operating Income-$34,114,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
TScan Therapeutics, Inc. · CIK 1783328 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$27,087,000N/M Margins · derivedOperating margin-6364.6%−5582.8 pt vs Q2 2023
Net margin-5906.9%−5143.1 pt vs Q2 2023
ended Jun 30, 2024 · filed Aug 12, 2024 · 43 d after period end